Department of Medical Microbiology, Faculty of Medicine, Üsküdar University, Istanbul, 34768, Turkey.
Department of Public Health, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Diagn Microbiol Infect Dis. 2024 Oct;110(2):116425. doi: 10.1016/j.diagmicrobio.2024.116425. Epub 2024 Jul 9.
The study aimed to evaluate the effect of booster dose COVID-19 vaccines on prevention and humoral immune response in individuals with different vaccination schemes during the period BA.4 and BA.5 omicron sub-variants were globally dominant. The study included 146 individuals who preferred different vaccination schemes for booster doses. Anti-spike/RBD-IgG and neutralizing antibody levels were measured 28 days after the booster dose vaccination upon their consent. There is no significant difference between median antibody titers detected according to different vaccination schemes. SARS-CoV-2 neutralizing antibody inhibition percentages were detected significantly higher in serum samples before and after the last booster dose in 2 BNT162b2+1 BNT162b2(99.42 %), 2 BNT162b2 + 2 BNT162b2(99.42 %), and 2 BNT162b2 + 3 BNT162b2(99.42 %) vaccination schemes (p = 0.004, p = 0.044, p = 0.002,respectively). The study indicated that a booster vaccination dose provides a high level of protection against severe COVID-19 and death. We think that the variant-specific pancoronavirus vaccines will be necessary to protect against breakthrough infections.
本研究旨在评估在 BA.4 和 BA.5 奥密克戎亚变种全球流行期间，不同疫苗接种方案的个体中，加强型 COVID-19 疫苗对预防和体液免疫应答的影响。该研究纳入了 146 名个体，他们选择了不同的加强型疫苗接种方案。在他们同意的情况下，在加强型疫苗接种后 28 天测量抗刺突蛋白/RBD-IgG 和中和抗体水平。根据不同的疫苗接种方案，检测到的抗体滴度中位数没有显著差异。在最后一剂加强型疫苗接种前后，血清样本中的 SARS-CoV-2 中和抗体抑制率在 2 BNT162b2+1 BNT162b2（99.42%）、2 BNT162b2+2 BNT162b2（99.42%）和 2 BNT162b2+3 BNT162b2（99.42%）接种方案中显著升高（p=0.004，p=0.044，p=0.002）。该研究表明，加强型疫苗接种剂量可提供针对严重 COVID-19 和死亡的高度保护。我们认为，针对变异的泛冠状病毒疫苗将是预防突破性感染所必需的。
